Scott Epstein
@Avoro Capital Advisors Llc
Latest period2024 - Q3ReportedManaged Assets$6.858BTotal holdings36
Assets growth rate-8.66%Assets growth rate (2-Q avg)-10.54%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Avoro Capital Advisors Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 36 positions.
Assets under management
The assets under management (AUM) of Avoro Capital Advisors Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 6.858B in assets, with a quarterly growth rate of -8.66% and a 2-quarter average growth rate of -10.54%. The portfolio is managed by Scott Epstein, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
XENEXenon Pharmaceuticals Inc
| 3.26% | $223.097M 5.667M shares@ $39.37 avg price | |
KYMRKymera Therapeutics Inc
| 3.11% | $212.985M 4.5M shares@ $47.33 avg price | Increased 15.72% |
VERAVera Therapeutics Inc
| 2.78% | $190.484M 4.31M shares@ $44.2 avg price | |
ARWRArrowhead Pharmaceuticals Inc.
| 2.52% | $172.178M 8.889M shares@ $19.38 avg price | |
BMRNBiomarin Pharmaceutical Inc
| 2.09% | $143.252M 2.038M shares@ $70.29 avg price | Decreased -55.28% |
MLTXMoonlake Immunotherapeutics
| 2.04% | $139.668M 2.77M shares@ $50.42 avg price | Increased 0.01% |
PCVXVaxcyte Inc
| 1.96% | $134.267M 1.175M shares@ $114.27 avg price | Increased 104.35% |
SLNOSoleno Therapeutics Inc
| 1.61% | $110.119M 2.181M shares@ $50.49 avg price | Increased 4.28% |
BCRXBiocryst Pharmaceuticals Inc
| 1.32% | $90.174M 11.865M shares@ $7.6 avg price | Decreased -5.6% |
SNDXSyndax Pharmaceuticals Inc
| 1.1% | $74.852M 3.888M shares@ $19.25 avg price |